HIV envelope: Challenges and opportunities for development of entry inhibitors

Trends in Microbiology

Volumn 19, Issue 4, 2011, Pages 191-197

  Caffrey, Michael ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; BETULIC ACID; BETULIC ACID DERIVATIVE; CD4 ANTIGEN; CELESTRI; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IBALIZUMAB; MARAVIROC; PRO 140; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; REVIEW; VIRUS ENTRY; VIRUS ENVELOPE;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV FUSION INHIBITORS; HUMANS; PROTEIN CONFORMATION; VIRUS INTERNALIZATION;

EID: 79953287011     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2011.02.001     Document Type: Review

References (90)

1. Fauci A. Twenty-five years of HIV/AIDS. Science 2006, 313:409.
2. Roux K., Taylor K. AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 2007, 17:244-252.
3. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15:690-698.
4. Adamson C.S., Freed E.O. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv. Pharmacol. 2007, 55:347-387.
5. Douglas N., et al. HIV/SIV glycoproteins: structure-function relationships. J. Mol. Biol. 1997, 273:122-149.
6. Kwong P., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing antibody. Nature 1998, 393:648-659.
7. Pancera M., et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1166-1171.
8. Chan D.C., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
9. Weissenhorn W., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
10. Caffrey M., et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 1998, 17:4572-4584.
11. Huang C., et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
12. Chen B., et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
13. Jaroniec C.P., et al. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry 2005, 44:16167-16180.
14. Sun Z.Y., et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28:52-63.
15. Liu J., et al. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry 2009, 48:2915-2923.
16. Buzon V., et al. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6:e1000880.
17. Bhattacharya A. Structures of desire. Nature 2009, 459:24-27.
18. Cao J., et al. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 1993, 67:2747-2755.
19. Delahunty M.D., et al. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. Virology 1996, 218:94-102.
20. Weng Y., Weiss C.D. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 1998, 72:9676-9682.
21. Salzwedel K., et al. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 1999, 73:2469-2480.
22. York J., Nunberg J. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J. Virol. 2004, 78:4921-4926.
23. Jacobs A., et al. Alanine scanning mutagenesis of the HIV gp41 loop. J. Biol. Chem. 2005, 280:27284-27288.
24. Sen J., et al. Role of the HIV gp120 conserved domain 5 in processing and viral entry. Biochemistry 2008, 47:7788-7795.
25. Wang J., et al. Role of the HIV gp120 conserved domain 1 in processing and viral entry. J. Biol. Chem. 2008, 283:32644-32649.
26. Sen J., et al. Alanine scanning mutagenesis of the HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry 2010, 49:5057-5065.
27. Finzi A., et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 2010, 37:656-667.
28. Kim S., et al. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 2008, 376:786-797.
29. Binley J., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74:627-643.
30. Abrahamyan L., et al. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J. Virol. 2003, 77:5829-5836.
31. Binley J., et al. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 2003, 77:5678-5684.
32. Kang Y.K., et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009, 27:5120-5132.
33. Dimitrov D.S., et al. HIV coreceptors. J. Membr. Biol. 1998, 166:75-90.
34. Miyauchi K., et al. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
35. Wingfield P., et al. The extracellular domain of immunodeficiency virus gp41 protein. Expression in Escherichia coli, purification, and crystallization. Protein Sci. 1997, 6:1653-1660.
36. Caffrey M., et al. Monomer-trimer equilibrium of the ectodomain of SIV gp41: insight into the mechanism of peptide inhibition of HIV infection. Protein Sci. 1999, 8:1904-1907.
37. Peisajovich S., Shai Y. SIV gp41 binds to membranes both in the monomeric and trimeric states: consequences for the neuropathology and inhibition of HIV infection. J. Mol. Biol. 2001, 311:249-254.
38. Bewley C., et al. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol.Chem. 2002, 277:14238-14245.
39. Sougrat R., et al. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007, 3:e63.
40. Liu J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
41. Zhu P., et al. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog. 2008, 4:e1000203.
42. Wild C., et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10537-10541.
43. Wild C., et al. Peptides corresponding to a predictive a-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:9770-9774.
44. Furuta R., et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 1998, 5:276-279.
45. Gaschen B., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
46. Reitter J., et al. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 1998, 4:679-684.
47. Wyatt R., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
48. Trkola A., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70:1100-1108.
49. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
50. Nuttall J. Microbicides in the prevention of HIV infection: current status and future directions. Drugs 2010, 70:1231-1243.
51. Hallenberger S., et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992, 360:358-361.
52. Khatib A.M., et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am. J. Pathol. 2002, 160:1921-1935.
53. Bahbouhi B., et al. Effects of L- and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication. Biochem. J. 2002, 366:863-872.
54. Kibler K.V., et al. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J. Biol. Chem. 2004, 279:49055-49063.
55. Van Rompaey L., et al. Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region. Biochem. J. 1997, 326:507-514.
56. Anderson E.D., et al. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J. Biol. Chem. 1993, 268:24887-24891.
57. Cordelier P., Strayer D.S. Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis. Biochim. Biophys. Acta 2003, 1638:197-207.
58. Blair W.S., et al. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrob. Agents Chemother. 2007, 51:3554-3561.
59. Sen J., et al. The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci. 2007, 16:1236-1241.
60. Hartley O., et al. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 2005, 21:171-189.
61. Lin P.F., et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11013-11018.
62. Si Z., et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5036-5041.
63. Lu R.J., et al. Heterobiaryl human immunodeficiency virus entry inhibitors. J. Med. Chem. 2009, 52:4481-4487.
64. Tran T.D., et al. Design and optimisation of potent gp120-CD4 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:5250-5255.
65. Zhou T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
66. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 2007, 5:583-597.
67. Xiong S., et al. The antiviral protein cyanovirin-N: the current state of its production and applications. Appl. Microbiol. Biotechnol. 2010, 86:805-812.
68. Lara H.H., et al. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnol. 2010, 8:1.
69. Lai W., et al. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2008, 52:128-136.
70. Biorn A.C., et al. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004, 43:1928-1938.
71. Umashankara M., et al. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem 2010, 5:1871-1879.
72. Westby M., van der Ryst E. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir. Chem. Chemother. 2010, 20:179-192.
73. Dau B., Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009, 69:31-50.
74. Bruno C.J., Jacobson J.M. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J. Antimicrob. Chemother. 2010, 65:1839-1841.
75. Muñoz-Barroso I., et al. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 1998, 140:315-323.
76. Matthews T., et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 2004, 3:215-225.
77. Horne W.S., et al. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14751-14756.
78. Welch B.D., et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 2010, 84:11235-11244.
79. Root M.J., et al. Protein design of an HIV-1 entry inhibitor. Science 2001, 291:884-888.
80. Louis J.M., et al. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 2001, 276:29485-29489.
81. Wang H., et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Chemother. 2009, 53:4987-4998.
82. Gonzalez-Ortega E., et al. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation. Antimicrob. Agents Chemother. 2010, 54:4487-4492.
83. Dimitrov A.S., et al. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 2007, 46:1398-1401.
84. Montero M., et al. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008, 72:54-84.
85. Frey G., et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3739-3744.
86. Weissenhorn W., et al. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 1998, 2:605-616.
87. Hakansson S., et al. The solution structure of the SARS coronavirus heptad repeat 2 in the prefusion state. J. Biol. Chem. 2006, 281:11965-11971.
88. Yin H., et al. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 2006, 439:38-44.
89. Ferrer M., Harrison S.C. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 1999, 73:5795-5802.
90. Ferrer M., et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 1999, 6:953-960.